Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 4468-4472, August 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chitambar, C. R.
Right arrow Articles by Antholine, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chitambar, C. R.
Right arrow Articles by Antholine, W. E.

Development of Drug Resistance to Gallium Nitrate through Modulation of Cellular Iron Uptake1

Christopher R. Chitambar2, Zorica Zivkovic-Gilgenbach, Jana Narasimhan and William E. Antholine

Division of Hematology-Oncology, Department of Medicine [C. R. C., Z. Z-G.], and National Biomedical ESR Center [J. N., W. E. A.], Medical College of Wisconsin, Milwaukee, Wisconsin 53226

We have shown that transferrin-gallium (Tf-Ga) blocks DNA synthesis through inhibition of cellular iron incorporation and a diminution in the activity of the iron-dependent M2 subunit of ribonucleotide reductase. To examine the mechanisms of drug resistance to gallium, we developed a subline of HL60 cells (R cells) which is 29-fold more resistant to growth inhibition by gallium nitrate than the parent line (S cells). R cells displayed a 2.5-fold increase in transferrin (Tf) receptor expression, without a change in receptor affinity for Tf. The uptake and release of 67Ga were similar for both S and R cells. The uptake of 59Fe-Tf by S cells was inhibited by gallium nitrate over 24–48 h of incubation. In contrast, 59Fe-Tf uptake by R cells, although initially inhibited by gallium nitrate at 24 h, was no longer inhibited at 48 h of incubation. 59FeCl3 uptake by R cells was significantly greater than that of S cells, regardless of the time in culture. Despite the increase in 59Fe uptake by R cells, the ferritin content of these cells was lower than that of S cells. The ribonucleotide reductase electron spin resonance signal of R cells was comparable to that of S cells. R cells were not cross-resistant to Adriamycin, vincristine, cis-platinum or hydroxyurea. Resistance to gallium nitrate in this subline of HL60 cells results primarily from the ability of cells to overcome the gallium-induced block in iron incorporation. In addition, intracellular iron in R cells appears to traffic preferentially to a non-ferritin compartment.

1 This work was supported by USPHS Grant RO1 CA41740 from the National Cancer Institute to C. R. C.

2 To whom requests for reprints should be addressed, at Division of Hematology/Oncology, Medical College of Wisconsin, 8700 W. Wisconsin Avenue, Milwaukee, WI 53226.

Received 10/27/89. Revised 1/16/90.


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. P. Davies, Y. S. Rahmanto, C. R. Chitambar, and D. R. Richardson
Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 153 - 162.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Heffeter, M. Pongratz, E. Steiner, P. Chiba, M. A. Jakupec, L. Elbling, B. Marian, W. Korner, F. Sevelda, M. Micksche, et al.
Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 281 - 289.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. M. Brown, M. C. Kennedy, W. E. Antholine, R. S. Eisenstein, and W. E. Walden
Detection of a [3Fe-4S] Cluster Intermediate of Cytosolic Aconitase in Yeast Expressing Iron Regulatory Protein 1. INSIGHTS INTO THE MECHANISM OF Fe-S CLUSTER CYCLING
J. Biol. Chem., February 22, 2002; 277(9): 7246 - 7254.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.